Biocompatibility and antifibrotic effect of UV-cross-linked hyaluronate as a release-system for tranilast after trabeculectomy in a rabbit modela pilot study

Current Eye Research

Volumn 37, Issue 6, 2012, Pages 463-470

  Spitzer, Martin S ^a   Sat, MacArena ^a,b   Schramm, Charlotte ^a   Schnichels, Sven ^a   Schultheiss, Maximilian ^a   Yoeruek, Efdal ^a   Dzhelebov, Dimitar ^c   Szurman, Peter ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b HOSPITAL DEL SALVADOR   (Chile)

^c TRAKIA UNIVERSITY   (Bulgaria)

Author keywords

Biopolymer; Cross linked hyaluronate; Glaucoma surgery; Hyaluronate; Slow release system; Tabeculectomy; Tranilast

Indexed keywords

HYALURONIC ACID; TRANILAST; ULTRAVIOLET CROSSLINKED HYALURONATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CLINICAL PRACTICE; CONNECTIVE TISSUE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSS LINKING; DRUG BINDING; DRUG EFFICACY; DRUG RELEASE; DRUG TOLERABILITY; ENCAPSULATION; FEMALE; FOLLOW UP; GLAUCOMA; HISTOLOGY; HYDROGEL; HYPHEMA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTRAOCULAR PRESSURE; INTRAOPERATIVE PERIOD; NONHUMAN; PRIORITY JOURNAL; RABBIT; TRABECULECTOMY; VISCOSITY;

ANIMALS; ANTHRANILIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOCOMPATIBLE MATERIALS; CELL PROLIFERATION; CROSS-LINKING REAGENTS; DRUG DELIVERY SYSTEMS; FIBROSIS; GLAUCOMA; HYALURONIC ACID; PILOT PROJECTS; RABBITS; TRABECULECTOMY; ULTRAVIOLET RAYS; VISCOSUPPLEMENTS;

EID: 84861027251     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2012.658593     Document Type: Article

References (42)

1. Addicks EM, Quigley HA, Green WR, Robin AL. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol. 1983;101:795-798.
2. Maumenee AE. External filtering operations for glaucoma: The mechanism of function and failure. Trans Am Ophthalmol Soc. 1960;58:319-328.
3. Cao Y, Da BH, Wei HR. The inhibitory effect of tranilast on transforming growth factor-β(2) expression in cultured human trabecular meshwork cells. Zhongua Yan Ke Za Zhi. 2004; 40:254-257.
4. Frank C, Spitzer MS, Henke-Fahle S, Yoeruek E, Bartz-Schmidt KU, Szurman P. The Cross-Linked Biopolymer Hyaluronic Acid as Artificial Vitreous Substitute. Invest Ophthalmol Vis Sci. 2009;50: ARVO E-Abstract: A4445.
5. Yamamoto M, Yamauchi T, Okano K, Takahashi M, Watabe S, Yamamoto Y. Tranilast, an anti-allergic drug, down-regulates the growth of cultured neurofibroma cells derived from neurofibromatosis type 1. Tohoku J Exp Med. 2009;217:193-201.
6. Sourdille P, Santiago PY, Villain F et al. Reticulated hyaluronic acid implant in nonperforating trabecular surgery. J Cataract Refract Surg. 1999;25:332-339.
7. Kaluzny JJ, Józwicki W, Wisniewska H. Histological biocompatibility of new, non-absorbable glaucoma deep sclerectomy implant. J Biomed Mater Res Part B Appl Biomater. 2007;81:403-409.
8. Stürmer J, Mermoud A, Sunaric Mégevand G. [Trabeculectomy with mitomycin C supplemented with cross-linking hyaluronic acid: A pilot study]. Klin Monbl Augenheilkd. 2010;227:273-276.
9. Spitzer MS, Yoeruek E, Kaczmarek RT et al. Sodium hyaluronate gels as a drug-release system for corticosteroids: Release kinetics and antiproliferative potential for glaucoma surgery. Acta Ophthalmol. 2008;86:842-848.
10. Tamm ER, Fuchshofer R. What increases outflow resistance in primary open-angle glaucoma? Surv Ophtalmol. 2007;52:101-104
11. Ji CN, Hu YZ, Ding ZP, Li GG. [The investigation of tranilast on the proliferation and migration of human Tenon's capsule fibroblasts]. Zhonghua Yan Ke Za Zhi. 2004;40:165-169.
12. Kondo S, Yamamoto M, Takeuchi A, Suzuki H, Iwaki M.[Anti-allergic drugs inhibit the proliferation of human Tenon's capsule fibroblast and maintain the experimental filtering blebs on rabbit eyes]. Nippon Ganka Gakkai Zasshi. 2002;106:325-331.
13. Oshima T, Kurosaka D, Kato K et al. Tranilast inhibits cell proliferation and collagen synthesis by rabbit corneal and Tenon's capsule fibroblasts. Curr Eye Res. 2000;20:283-286.
14. Da B, Cao Y, Wei H, Chen Z, Shui Y, Li Z. Antagonistic effects of tranilast on proliferation and collagen synthesis induced by TGF-β2 in cultured human trabecular meshwork cells. J Huazhong Univ Sci Technol Med Sci. 2004;24:490-2, 496.
15. Isaji M, Kikuchi S, Miyata H et al. Inhibitory effects of tranilast on the proliferation and functions of human pterygiumderived fibroblasts. Cornea. 2000;19:364-368.
16. Lee MJ, Jin SE, Kim CK et al. Slow-releasing tranilast in polytetrafluoroethylene/ polylactide-co-glycolide laminate delays adjustment after strabismus surgery in rabbit model. Invest Ophthalmol Vis Sci. 2007;48:699-704.
17. Furukawa H, Nakayasu K, Gotoh T et al. Effect of topical tranilast and corticosteroids on subepithelial haze after photorefractive keratectomy in rabbits. J Refract Surg. 1997;13:S457-S458.
18. Okamoto S, Sakai T, Iwaki Y, Tobari I, Hamano S. Effects of tranilast on cultured rabbit corneal keratocytes and corneal haze after photorefractive keratectomy. Jpn J Ophthalmol. 1999;43:355-362.
19. Sakai T, Okamoto S, Iwaki Y. [The effect of tranilast on subepithelial corneal opacity after excimer laser keratectomy]. Nippon Ganka Gakkai Zasshi. 1997;101:783-787.
20. Song JS, Jung HR, Kim HM. Effects of topical tranilast on corneal haze after photorefractive keratectomy. J Cataract Refract Surg. 2005;31:1065-1073.
21. Tani E, Katakami C, Negi A. [Effects of various eye drops on corneal wound healing after superficial keratectomy in rabbits]. Nippon Ganka Gakkai Zasshi. 2002;106:135-142.
22. Matsushima H, Mukai K, Gotoo N et al. The effects of drug delivery via hydrophilic acrylic (hydrogel) intraocular lens systems on the epithelial cells in culture. Ophthalmic Surg Lasers Imaging. 2005;36:386-392.
23. Tobari I, Iwaki Y, Miyake K. Effect of tranilast eyedrops in preventing posterior capsule opacification: Preliminary report. J Cataract Refract Surg. 1999;25:1394-1399.
24. Wang M, Zhang JJ, Jackson TL, Sun X, Wu W, Marshall J. Safety and efficacy of intracapsular tranilast microspheres in experimental posterior capsule opacification. J Cataract Refract Surg. 2007;33:2122-2128.
25. Ito S, Sakamoto T, Tahara Y et al. The effect of tranilast on experimental proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1999;237:691-696.
26. Koyama S, Takagi H, Otani A, Suzuma K, Nishimura K, Honda Y. Tranilast inhibits protein kinase C-dependent signalling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells. Br J Pharmacol. 1999;127:537-545.
27. Takehana Y, Kurokawa T, Kitamura T et al. Suppression of laser-induced choroidal neovascularization by oral tranilast in the rat. Invest Ophthalmol Vis Sci. 1999;40:459-466.
28. Leach JB, Bivens KA, Collins CN, Schmidt CE. Development of photocrosslinkable hyaluronic acid-polyethylene glycolpeptide composite hydrogels for soft tissue engineering. J Biomed Mater Res A. 2004;70:74-82.
29. Grisanti S, Szurman P, Warga M et al. Decorin modulates wound healing in experimental glaucoma filtration surgery: A pilot study. Invest Ophthalmol Vis Sci. 2005;46:191-196.
30. Lopes JF, Moster MR, Wilson RP et al. Subconjunctival sodium hyaluronate 2.3% in trabeculectomy: A prospective randomized clinical trial. Ophthalmology. 2006;113:756-760.
31. Chakrabarti R, Subramaniam V, Abdalla S, Jothy S, Prud'homme GJ. Tranilast inhibits the growth and metastasis of mammary carcinoma. Anticancer Drugs. 2009;20:334-345.
32. Izumi K, Mizokami A, Li YQ et al. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor β1-associated osteoblastic changes. Prostate. 2009;69:1222-1234.
33. Cui H, Gensini M, Kataria R et al. Reducing post-surgical adhesions utilizing a drug-enhanced device: Sodium carboxymethylcellulose aqueous gel/poly(p-dioxanone) and Tranilast. Biomed Mater. 2009;4:015001.
34. Singh M, Williams BA, Gersh BJ et al. Geographical differences in the rates of angiographic restenosis and ischemia-driven target vessel revascularization after percutaneous coronary interventions: Results from the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) Trial. J Am Coll Cardiol. 2006;47:34-39.
35. Cooper K, Young J, Wadsworth S, Cui H, diZerega GS, Rodgers KE. Reduction of post-surgical adhesion formation with tranilast. J Surg Res. 2007;141:153-161.
36. Petrilli J, Wadsworth S, Cooper K, Rodgers KE, Siekierka J, diZerega GS. Tranilast: A pharmaceutical candidate for reduction of adhesions using a novel approach. Semin Reprod Med. 2008;26:341-348.
37. Inglis JJ, Criado G, Andrews M, Feldmann M, Williams RO, Selley ML. The anti-allergic drug, N-(3',4'- dimethoxycinnamonyl) anthranilic acid, exhibits potent anti-inflammatory and analgesic properties in arthritis. Rheumatology (Oxford). 2007;46:1428-1432.
38. Soma J, Sugawara T, Huang YD, Nakajima J, Kawamura M. Tranilast slows the progression of advanced diabetic nephropathy. Nephron. 2002;92:693-698.
39. Soma J, Sato K, Saito H, Tsuchiya Y. Effect of tranilast in early-stage diabetic nephropathy. Nephrol Dial Transplant. 2006;21:2795-2799.
40. Chihara E, Dong J, Ochiai H, Hamada S. Effects of tranilast on filtering blebs: A pilot study. J Glaucoma. 2002;11:127-133.
41. CAT-152 0102 Trabeculectomy Study Group, Khaw P, Grehn F, Holls G, Overton B, Wilson R, Vogel R, Smith Z. A phase III study of subconjunctival human anti-transforming growth factor β(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology. 2007; 114:1822-1830.
42. Chien YW: In Novel drug delivery systems., 2nd edn 1992. New York: Marcel Dekker, 43-137.